title: Association of GSTO2 (N142D), GSTT1, and GSTM1 Polymorphisms With Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
abstract: OBJECTIVE
  Graft-versus-host disease is a major problem after bone marrow transplant. GSTM1, GSTT1, and GSTO2 are important genes that interfere with xenobiotic and drug metabolism. Polymorphisms of these genes may influence the metabolism of immunosuppressive drugs given for inhibition of graft-versus-host disease and may influence their susceptibility to diseases, which bone marrow transplant could alleviate.
  
  
  METHODS
  We examined the polymorphisms of 2 groups: The first group was composed of 88 patients who had undergone a bone marrow transplant and 100 otherwise healthy persons; the second group was composed of 54 patients without graft-versus-host disease and 34 patients with graft-versus-host disease. We used polymerase chain reaction-restriction fragment length polymorphism method for genotyping GSTO2 and also for multiplexing polymerase chain reactions for GSTT1 and GSTM1 genotypes.
  
  
  RESULTS
  No significant association existed between the genotypes GSTO2 (DD: P = .458, OR 0.422), GSTM1 (P = .349, OR 1.52), or GSTT1 (P = .887, OR 1.086), and the incidence of GVHD. Moreover, we saw no association between these polymorphisms and the problems that lead to bone marrow transplant (GSTO2: DD, P = .181, OR 0.465; GSTM1: P = .699, OR 0.892; GSTT1: P = .656, OR 0.845). We showed that men have more bone marrow transplants than do women (P = .019, OR 2.034).
  
  
  CONCLUSIONS
  Our results show that these poly-morphisms may have no effect on the metabolism of drugs used to treat graft-versus-host disease and also, may play no significant role in creating the problems that lead to bone marrow transplant.
authors.affiliation: From the Department of Biology, College of Sciences, Shiraz University, Shiraz, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Khosravi
authors.forename: Mansoureh
authors.initials: M
authors.lastname: Izaddoust
authors.forename: Iraj
authors.initials: I
authors.lastname: Saadat
authors.forename: Mohammad Hossein
authors.initials: MH
authors.lastname: Karimi
authors.forename: Mani
authors.initials: M
authors.lastname: Ramzi
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D002648:Child; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005982:Glutathione Transferase / Q000235:genetics*; D006086:Graft vs Host Disease / Q000201:enzymology / Q000235:genetics* / Q000276:immunology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D060885:Multiplex Polymerase Chain Reaction; D016017:Odds Ratio; D010597:Pharmacogenetics; D000071185:Pharmacogenomic Testing / Q000379:methods; D000071184:Pharmacogenomic Variants; D010641:Phenotype; D012307:Risk Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005982:Glutathione Transferase; D007166:Immunosuppressive Agents; C413545:glutathione S-transferase T1; C492569:GSTO2 protein, human